Soleno Therapeutics, Inc. (NASDAQ:SLNO) marched up 3.85% compared to a 52-week low price of $1.3. The shares were last seen trading -3.57% lower, taking the closing price at $1.35 on 3/14/2019. At a recent session, the prices were hovering between $1.11 and $1.38. This company shares are 937.04% off its target price of $14 and the current market capitalization stands at $29.88M. The recent change has given its price a -19.03% deficit over SMA 50 and -62.5% deficit over its 52-week high. The stock witnessed -18.18% declines, -21.51% declines and -31.47% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SLNO’s volatility during a week at 12.85% and during a month it has been found around 8.85%.Soleno Therapeutics, Inc. (SLNO) Top Holders
Institutional investors currently hold around $22 million or 88.4% in SLNO stock. Look at its top three institutional owners: Abingworth Llp owns $6.54 million in Soleno Therapeutics, Inc., which represents roughly 21.88% of the company’s market cap and approximately 29.71% of the institutional ownership. Similar statistics are true for the second largest owner, Vivo Capital, Llc, which owns 4,359,683 shares of the stock are valued at $6.1 million. The third largest holder is Oracle Investment Management Inc, which currently holds $5.16 million worth of this stock and that ownership represents nearly 17.26% of its market capitalization.Soleno Therapeutics, Inc. 13F Filings
At the end of December reporting period, 9 institutional holders increased their position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by some 6,243,466 shares, 7 decreased positions by 289,976 and 7 held positions by 8,926,315. That puts total institutional holdings at 15,459,757 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 4,854,089 shares while 3 institutional investors sold out their entire positions totaling 59,221 shares.Soleno Therapeutics, Inc. (SLNO) Analyst Guide
Not many analysts have released their opinion on Soleno Therapeutics, Inc. (NASDAQ:SLNO), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].